| Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study F Valldeoriola, J Puig-Junoy, R Puig-Peiró, ... Journal of medical economics 16 (2), 191-201, 2013 | 46 | 2013 |
| Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs A Gilabert-Perramon, J Torrent-Farnell, A Catalan, A Prat, M Fontanet, ... International journal of technology assessment in health care 33 (1), 111, 2017 | 32 | 2017 |
| The use of pay-for-performance for drugs: Can it improve incentives for innovation? A Towse, L Garrison, R Puig-Peiró Incentives for Research, Development, and Innovation in Pharmaceuticals, 69-80, 2011 | 12 | 2011 |
| Understanding variations in relative effectiveness: A health production approach A Towse, B Jonsson, C McGrath, A Mason, R Puig-Peiro, ... International journal of technology assessment in health care 31 (6), 363-370, 2015 | 10 | 2015 |
| Projecting expenditure on medicines in the UK NHS P O’Neill, J Mestre-Ferrandiz, R Puig-Peiro, J Sussex PharmacoEconomics 31 (10), 933-957, 2013 | 10 | 2013 |
| Impacto económico de las exacerbaciones agudas en EPOC desde la perspectiva del SNS español M Pérez, R Puig-Peiró, S Aceituno, L Lizán Rev Patol Respir 19 (3), 88-95, 2016 | 9 | 2016 |
| Cost–effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain D Nieves, R Puig-Peiró, C Ferrándiz, MJ Plazas, M Brosa Expert review of pharmacoeconomics & outcomes research 15 (3), 539-543, 2015 | 6 | 2015 |
| RS1 Literature Review On Patient Access Schemes, Flexible Pricing Schemes And Risk Sharing Agreements For Medicines R Puig-Peiró, J Mestre-Ferrandiz, J Sussex, A Towse Value in Health 14 (7), A243, 2011 | 6 | 2011 |
| La financiación del sistema para la autonomía y atención a la dependencia: proyecciones de gasto 2007-2015 D Casado Marín, A Tur Prats, R Puig Peiró Madrid: IMSERSO, 2008 | 6 | 2008 |
| Researching the relative efficacy and relative effectiveness of medicines across Europe J Mestre-Ferrandiz, R Puig-Peiró, A Towse Consulting Reports, 2010 | 5 | 2010 |
| Revisión de la evidencia económica sobre el uso de la estimulación cerebralprofunda en la enfermedad de Parkinson avanzada J Puig-Junoy, R Puig Peiró Neurologia 24, 220-229, 2009 | 5 | 2009 |
| HT5 Development of a Multi-Criteria Decision Analysis (MCDA) Framework for health care decision-making in catalonia (spain): pilot study focused in orphan drugs A Gilabert-Perramon, J Torrent-Farnell, A Catalan, A Prat, M Fontanet, ... Value in Health 19 (7), A353, 2016 | 3 | 2016 |
| Coste directo de la Enfermedad Pulmonar Obstructiva Crónica asociado a variaciones en adherencia y persistencia M Pérez, S Paz, L Lizán Rev Patol Respir 18, 49-56, 2015 | 3 | 2015 |
| Relative effectiveness in breast cancer treatment: A health production approach R Puig-Peiro, A Mason, J Mestre-Ferrandiz, A Towse, C McGrath, ... International journal of technology assessment in health care 31 (6), 371-379, 2015 | 2 | 2015 |
| Incentivos a la I+ D+ i de medicamentos WA Garcia-Fontes Springer Science & Business Media, 2012 | 2 | 2012 |
| Letter to the editor regarding the paper by A. Lozano-Blázquez et al. Differences in cancer drug assessment between Spain and the United Kingdom A Prat, A Gilabert, R Puig-Peiro, A Feliu, M Riba, MA Mangues, ... European Journal of Cancer 67, 55-56, 2016 | 1 | 2016 |
| INSTRUMENTS FOR THE INCORPORATION OF ECONOMIC EVALUATION, BUDGETARY IMPACT AND SCHEMES OF PAYMENT BY RESULTS IN THE CATALAN HEALTH SERVICE (SPAIN) M Brosa, J Puig-Junoy, M Gasol-Boncompte, L Segu-Tolsa, ... VALUE IN HEALTH 18 (7), A855-A855, 2015 | 1 | 2015 |
| Instrumentos Para la Incorporacion de la Evaluacion Economica, el Impacto Presupuestario y Los Esquemas de Pago por Resultados en el Servicio Catalán de Salud (España) M Brosa, J Puig-Junoy, M Gasol-Boncompte, L Segú-Tolsà, ... Value in Health 18 (7), A855, 2015 | 1 | 2015 |
| International Comparisons of Medicines Prices: 2011 Indices P O'Neill, R Puig-Peiro, J Mestre-Ferrandiz, J Sussex Consulting Reports, 2012 | 1 | 2012 |
| Time trends in NICE HTA decisions P O'Neill, N Devlin, R Puig-Peiro Consulting Reports, 2012 | 1 | 2012 |
Anne MasonSenior Research Fellow, University of York, York, UKCorreu electrònic verificat a york.ac.uk
